Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Stress, Burnout & Well-being stories

Oct 9, 2026

Outro raises $7 million to expand safe deprescribing platform for psychiatric medications

Outro, a New York-based neuroscience platform that helps patients safely discontinue psychiatric medications, announced it raised $7 million in combined pre-seed and seed funding. The funding will support the company's mission to close America's deprescribing gap and advance research in partnership with academic institutions.

Oct 9, 2026·2 sources
00
Sep 23, 2026

Cutting Ultra-Processed Foods May Improve Depression Symptoms, UCSF Pilot Study Finds

A UCSF pilot trial published in JAMA Psychiatry shows reducing ultra-processed food intake improves depression symptoms.

Sep 23, 2026·3 sources
00
Sep 21, 2026

Array Behavioral Care launches new triage model for urgent mental health care

Array Behavioral Care, a Chicago-based virtual behavioral health provider, introduced a new triage and routing capability designed to help healthcare providers better respond to patients requiring urgent mental health care.

Sep 21, 2026·1 source
00

FDA grants breakthrough therapy designation for DT120 ODT in depression treatment

The FDA has granted breakthrough therapy designation to Definium Therapeutics' DT120 Orally Disintegrating Tablet after preliminary clinical evidence showed significant improvements in treating major depressive disorder.

Sep 21, 2026·1 source
00
Sep 19, 2026

Telehealth companies face scrutiny over repeated customer medical data exposures

Multiple telehealth companies offering quick prescriptions for sensitive conditions like weight loss, sexual health, and mental health are repeatedly exposing customers' private medical data due to gaps in U.S. health privacy regulations. The FTC has filed suit against Hims & Hers over data practices and prescribing standards.

Sep 19, 2026·6 sources
00
Sep 17, 2026

Xenon Pharmaceuticals pauses depression drug trials over neuropsychiatric side effects

Xenon Pharmaceuticals temporarily halted new patient enrollment in clinical studies of its experimental depression drug following reports of mental health-related adverse events, causing shares to fall.

Sep 17, 2026·3 sources
00

Nearly half of physicians considered career changes due to well-being concerns, survey finds

A new survey of 1,000 doctors by a physician advocacy group found that nearly half have made or considered major career changes in the past year due to well-being concerns, with a widening mental health gap between employed and independent physicians.

Sep 17, 2026·1 source
00
Sep 15, 2026

Air pollution linked to higher suicide risk, research suggests

A major international meta-analysis found that both short- and long-term exposure to common air pollutants — particularly fine particulate matter (PM2.5) and nitrogen dioxide — are significantly associated with an increased risk of death by suicide, suicide attempts, and suicidal ideation.

Sep 15, 2026·1 source
00
Sep 14, 2026

Definium's LSD-based drug succeeds in third Phase 3 anxiety trial

Definium Therapeutics reported that its oral LSD-based treatment DT120 reduced symptoms of generalized anxiety disorder in a second successful late-stage study, marking the company's third Phase 3 win this year for the candidate.

Sep 14, 2026·2 sources
00
Sep 9, 2026

FDA suggests regulatory flexibility for assessing psychedelic therapies

The FDA indicated openness to innovative approaches for studying psychedelic therapies, including the use of comparators other than placebo, signaling potential regulatory accommodation for this emerging treatment class.

Sep 9, 2026·2 sources
00
Aug 12, 2026

Definium reports positive Phase 3 results for single-dose DT120 in generalized anxiety disorder

Definium Therapeutics announced its experimental LSD-based pill significantly reduced anxiety symptoms in a late-stage study, meeting the trial's main goal. The results mark the company's second major win in two months and sent shares up more than 20% in premarket trading.

Aug 12, 2026·2 sources
00
Aug 6, 2026

UK's First Publicly Funded Trial Shows Psilocybin Significantly Improves Treatment-Resistant Depression

A randomized controlled trial conducted through the NHS in England found that a single dose of psilocybin, the active compound in magic mushrooms, produced significant improvements in depression symptoms among 60 adults with treatment-resistant major depressive disorder compared to placebo, with good tolerability.

Aug 6, 2026·4 sources
00
Jul 13, 2026

HHS & VA Partner to Advance Psychedelic Therapies for Veterans

HHS and the VA signed a five-year Memorandum of Understanding on July 13, 2026, to collaborate on research, clinical development, and deployment of rapid-acting psychedelic drug products for veterans with serious mental illness and substance use disorders, pending FDA approval.

Jul 13, 2026·1 source
00
Jul 7, 2026

Compass Pathways' Psilocybin Therapy Shows Durable Benefits for Treatment-Resistant Depression in Pivotal Trial

Compass Pathways reported results from a pivotal study showing its psilocybin-based therapy demonstrated long-lasting benefits for treatment-resistant depression, though investor reaction was mixed as shares fell nearly 10% on the data.

Jul 7, 2026·2 sources
00
Jun 22, 2026

Definium's LSD-Based Pill Reduces Depression Symptoms in Late-Stage Trial

Definium Therapeutics reported that a single dose of its LSD-based experimental pill significantly reduced symptoms of major depression in patients in a late-stage trial, sending shares higher. The data brings the drug closer to potential FDA approval.

Jun 22, 2026·2 sources
00
May 8, 2026

Kennedy Health Officials Explore U.S. Ban on Certain SSRI Antidepressants

Health officials under Robert F. Kennedy Jr. explored banning certain SSRI antidepressants as part of plans to reduce their use in the United States, sparking significant debate over medication safety and federal regulatory authority.

May 8, 2026·1 source
00
Apr 23, 2026

Launch of 988 National Suicide Hotline Associated with 11% Drop in Youth Suicide Rates

A new study shows that suicide rates among young people dropped 11% following the U.S. launch of the 988 national suicide and crisis hotline, with increased calls to the hotline correlating with reduced suicide deaths.

Apr 23, 2026·1 source
00

Scientists Identify Brain Cells Linked to Depression for the First Time

Researchers identify specific brain cell types and neural circuits linked to depression, offering new insight into underlying biology and potential targets for more precise treatments.

Apr 23, 2026·2 sources
00
Apr 11, 2026

AI Analysis of Suicide Reports Finds Emotional Distress May Precede 90% of Deaths

UCLA-led study analyzing 72,585 suicide reports using AI found that current national reporting significantly underestimates the extent of emotional dysregulation occurring before suicide deaths.

Apr 11, 2026·1 source
00
Apr 6, 2026

Antidepressant Shows Promise in Reducing Methamphetamine Use

A new study demonstrates that a common antidepressant helps people cut back on methamphetamine use, offering potential treatment option for highly addictive stimulant.

Apr 6, 2026·1 source
00

Top claims

  • ▪Outro was co-founded by health technology entrepreneur Brandon Goode and psychiatric researcher Dr. Mark Horowitz, with headquarters in New York.
  • ▪Deprescribing protocols are largely absent from U.S. medical training, leaving clinicians and patients without formal guidance for stopping psychiatric medications.
  • ▪Outro's flagship Taper Management program for psychiatric medication deprescribing is available in 14 U.S. states.

People involved

Robert F. Kennedy Jr.

Subtopics

Mental Health & Wellbeing20Depression8Drug Approval and Clinical Trials8Drug Policy, Pricing & Approval8Psychedelic clinical research & trials7Psychedelic policy & regulation5LSD3Psychedelic-assisted therapy3Anxiety2Clinical evaluation2Clinical Trial Design & Evaluation2FDA considers first psychedelic drug approval2Healthcare technology2Psilocybin2Psychedelic renaissance2Suicide prevention2Accelerated approval pathways1Addiction & recovery1AI data analysis1AI privacy & surveillance1AI research & benchmarks1AI startups1Air pollution & respiratory health1Brain health & dementia researchers1

Related timelines

Trump administration

161 stories

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Russia-Ukraine war

136 stories